Lyme disease is a multisystem illness caused by the spirochete Borrelia burgdorferi (32) . The symptoms appearing after infection include a typical skin rash in the early stages of the disease as well as disorders in the musculoskeletal, cardiovascular, and/or central nervous system in the late stages of infection (45, 47) . The different clinical manifestations of disease depend on many factors, including the genetic background of the host and the virulence of the infecting spirochetes (1, 25, 46) . CD4 ϩ helper T-cell (Th) type 1 responses against the spirochete have been implicated as factors in human Lyme arthritis (50, 51) . In the mouse model, joint swelling tends to be more severe in mice that produce high levels of gamma interferon (IFN-␥) and joint swelling can be modulated by treatment with an anti-IFN-␥ monoclonal antibodies (MAb) (27, 33) . Similarly, in vivo blockade of interleukin-12 (IL-12), another major inducer of Th1 responses, results in reduced severity of acute murine Lyme arthritis (2) .
B7-1-and B7-2-mediated costimulation influences T-cell activation and differentiation and may therefore affect the course of murine Lyme borreliosis. Interaction between B7-1/B7-2 (B7) and CD28 is essential for the primary activation of T cells, and the failure of such signals may produce T-cell unresponsiveness or anergy (13, 23) . Antibody-blocking experiments suggest that B7-2 is the major CD28 ligand that initiates CD28-dependent costimulation in unprimed T cells (48) . In contrast, B7-1 costimulation appears to be upregulated later during activation of an immune response (48) . Moreover, CD28 costimulation may be more important for Th2 than for Th1 differentiation (48) . The administration of CTLA4Ig, which blocks the CD28-B7 pathway, causes a reduction in the severity of experimental leishmaniasis in BALB/c mice, a strain that normally develops progressive infection and a predominant Th2 response to the parasite (15) . In contrast, CTLA4Ig does not influence Leishmania infection in C57BL/6 mice, in which the immune response is Th1 dominated (15) . In other studies, the in vivo blockade of B7-1 produced a shift toward a Th2 response and a corresponding amelioration of experimental allergic encephalomyelitis while treatment with anti-B7-2 produced a dominant Th1 response and a worsening of disease (29) . Because of the ability of B7-1 and B7-2 to influence the outcome of autoimmune and infectious diseases that are dependent, at least in part, upon Th1-and Th2-mediated responses, we tested the effects of blocking B7-1 and B7-2 signalling on the course of murine Lyme disease.
MATERIALS AND METHODS
Mice. C3H/HeNCr (C3H) mice, 3 and 6 weeks old, were purchased from Frederick Cancer Research Center, Frederick, Md. The mice were housed in filter frame cages and sacrificed with CO 2 .
Infection of mice with B. burgdorferi. A clonal low-passage B. burgdorferi N40 strain (cN40) with proven infectivity and pathogenicity was used throughout the studies (6) . Spirochetes were grown in modified Barbour-Stoenner-Kelly (BSK) II medium at 33°C. Individual mice were challenged with a dose of 10 4 spirochetes administered by intradermal injection in the back, as previously described (21) .
The mice were sacrificed 14 days after inoculation and assessed for infection by culturing spleen, blood, urinary bladder, and skin (at the inoculation site) (20) . The cultures were read after 14-day incubations at 33°C, a sufficient period to allow a single spirochete to grow to the stationary phase.
Antibodies and in vivo treatment. Anti-B7-1 (1G10) and anti-B7-2 (2D10) MAbs were kindly provided by Denise Faherty (Hoffman-LaRoche, Nutley, N.J.), and have been extensively characterized (11-13, 29, 30, 37, 39) . Previous observations indicated that the administration of these MAbs does not produce cell depletion (data not shown). Normal rat immunoglobulin G (IgG) and phosphate-buffered saline (PBS) were used as controls. The antibodies were intraperitoneally injected into the mice, starting the day before spirochete inoculation, daily for three more days, and then every other day through day 14. The doses were 100 g, 500 g, and 1 mg in 100 l (in PBS) per injection when the antibody was injected alone, and half of each antibody when they were injected together (29, 39) .
Splenoccytes and CD4 ؉ T-cell purification and in vitro assays. After the mice were sacrificed, whole splenocytes were obtained by mechanical disruption and depletion of erythrocytes. Splenic CD4 ϩ T cells were purified by negative selection with mouse anti-I-A k (clone 10-3.6) and rat anti-mouse CD8a (clone 53-6.7) (Pharmingen, San Diego, Calif.) and goat anti-mouse and goat anti-rat IgG bound to magnetic beads (PerSeptive Diagnostics, Cambridge, Mass.). The purity of the CD4 ϩ T cells was Ͼ94%, as measured by fluorescence-activated cell sorter analysis (2 Flow cytometric analysis. Single-cell suspensions of splenocytes were stained by using 10 6 cells in 100 l with a panel of biotin (Bio)-, phycoerythrin (PE)-, or fluorescein isothiocyanate (FITC)-labeled antibodies for surface markers, i.e., CD4-PE, B220-FITC, Mac-1-Bio, B7-1-PE, and B7-2-PE, for 30 min at 4°C. Secondary staining for Mac-1-Bio-stained cells was performed, after washing the cells twice in PBS plus 1% fetal calf serum (FCS), with FITC-labeled streptavidin. After the final antibody incubation, the cells were washed twice and analyzed in a flow cytometer with the Cell Quest software package (Becton Dickinson, Franklin Lakes, N.J.).
RNA purification and RT-PCR. Whole splenocytes depleted of erythrocytes were used to extract RNA by the thioisocyanate method (14) by using the reagents and protocol of the Micro RNA isolation kit as specified by the manufacturer (Stratagene, La Jolla, Calif.). A 5-to 10-g portion was used to obtain cDNA with a reverse transcription PCR (RT-PCR) kit (Stratagene) with random primers. Semiquantitative competitive PCR was performed as described previously (38) with the polycompetitor cDNA construct pPQRS (38) . The oligonucleotide primers used for IL-2, IL-4, IL-10, IL-12, IFN-␥, and hypoxanthine phosphoribosyltransferase were synthesized as described previously (38) . Conditions of the PCR were as described previously (94°C for 20 s, 60°C for 40 s, and 72°C for 20 s for 35 cycles) (38) .
ELISA and Western blotting to detect B. burgdorferi-specific antibodies. B. burgdorferi-specific IgG and IgM levels in sera from the infected animals were determined by an enzyme-linked immunosorbent assay (ELISA). Briefly, samples were tested at 1/100 dilutions (2) with ELISA plates (ICN Pharmaceuticals) coated overnight at 4°C with 0.5 g of a B. burgdorferi lysate per ml of coating buffer (bicarbonate buffer [pH 9.6]). Before incubation with the sera at 37°C for 1 h, the plates were incubated with blocking buffer (PBS plus 10% fetal calf serum) for 2 h at room temperature. The secondary antibodies used were antimouse IgG and anti-mouse IgM conjugated with horseradish peroxidase (Sigma Chemical Co., St. Louis, Mo.) (dilution 1/2,000) for 1 h at room temperature. Extensive washes with PBS plus Tween 20 (0.5%, vol/vol) were performed between incubations. The plates were read at 450 nm after addition of peroxidase substrate (TMB; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) and stopping of the reaction, when completed, with TMB 1 component Stop Solution (Kirkegaard & Perry Laboratories, Inc.).
Specific patterns of protein recognition in infected mice were analyzed by Western blotting with B. burgdorferi cN40 lysate as the target. The blots were blocked for 2 h with PBS-3% bovine serum albumin (fraction V, United States Biochemicals, Cleveland, Ohio) and then incubated with dilutions of the sera (1/200 for 14-day-infected mouse sera and 1/50 for OspA-immunized mouse sera). After a 1-h incubation, the blots were washed and incubated with the secondary antibody (anti-mouse IgG plus IgM; 1/1,000 dilution each) conjugated to alkaline phosphatase (Sigma Chemical Co.). The blots were developed with TMB substrate (Kirkegaard & Perry Laboratories, Inc.).
ELISA for detection of IFN-␥ in serum. The amount of IFN-␥ present in pooled sera was measured by ELISA with antibodies specific for murine IFN-␥ (Pharmingen) (2) . Briefly, 96-well ELISA plates (ICN) were coated with the capture antibody (2 g/ml) overnight at 4°C. After blocking with PBS-10% FCS (PBS-FCS) for 2 h at room temperature, the samples were applied to the plates and incubated for 1 h at 37°C. The biotinylated detection antibody (1 g/ml) was added after the plates were washed with PBS-Tween 20 (0.5%, vol/vol) (PBSTween). Cytokine levels were quantitated after incubation of the plates with horseradish-conjugated avidin and addition of the substrate for the enzyme (TMB) and stop solution (TMB 1 component stop solution). The values indicated were calculated by comparing the values obtained with those derived by using standard concentrations of recombinant mouse IFN-␥ (Pharmingen). The sensitivity of the assays was determined to be less than 1 U/ml.
Histopathology of murine Lyme disease. The hearts and joints (both knees and tibiotarsi) were fixed in formalin, embedded in paraffin, and examined microscopically for evidence of disease (19) . The prevalence of arthritis was assessed by examination of both knees and tibiotarsal joints from each mouse. The severity of the tibiotarsal arthritis was scored on a scale of 0 (no disease) to 3 (severe disease) as described previously (19) . Active arthritis was scored, tabulated, and distinguished from resolving lesions (no active exudation). Carditis involved aortic and coronary endarteritis with inflammation of surrounding connective tissue and was not graded (3, 6, 7) . All the determinations and gradings were made in a blinded fashion.
RESULTS
Induction of B7-1 and B7-2 by B. burgdorferi in vivo. We first studied the expression of B7-1 and B7-2 on B cells and macrophages induced by B. burgdorferi upon infection. We checked the temporal induction of both costimulatory molecules in vivo at different time points after B. burgdorferi infection. The percentage of B7-2-expressing B cells and macrophages was increased over that in naive mice as early as 3 days after infection, reaching a peak on day 7 postchallenge (Fig. 1) . The percentage of B7-1-expressing macrophages was slightly augmented on days 7 and 9 of infection (Fig. 1) . On day 14, the percentages of B7-expressing B cells and macrophages were similar to those in naive uninfected mice. These data indicate that B. burgdorferi infection induces B7 molecules upon infection of C3H mice.
Functional effect of the treatment with anti-B7-1 and anti-B7-2 during B. burgdorferi infection. We then assessed the effect of the treatments with anti-B7-1 and/or B7-2 on B. burgdorferi-infected mice by determining the in vitro proliferative responses of CD4 ϩ T cells to B. burgdorferi antigens and of whole splenocytes to ConA and anti-IgM [F(abЈ) 2 ], as well as the cytokine pattern of expression in the spleens of the infected mice. No differences in cell proliferation in response to B. burgdorferi were observed between anti-B7-1 and/or anti-B7-2 MAb-treated and control mice (analysis of variance; P Ͼ 0.25 [ Fig. 2A]) . The ConA and anti-IgM responses were, nevertheless, impaired in anti-B7-1-and/or anti-B7-2-treated infected mice ( Fig. 2B and C) . The analysis of variance gave P values lower than 0.0001 in both cases.
We then determined whether the anti-B7-1 and anti-B7-2 MAb treatments affected the pattern of cytokine production by whole splenocytes by using a semiquantitative competitive RT-PCR for IL-2, IL-4, IL-10, IL-12, and IFN-␥ (data not shown). Splenocytes from noninfected mice did not produce, as expected, detectable levels of these cytokines. The analysis of B. burgdorferi-infected and B7-1 and/or B7-2 antibody-treated mice at different time points after infection revealed no differences in cytokine mRNA production, suggesting that the treatment with the B7 MAbs does not produce major differences in mRNA production by splenocytes of B. burgdorferi-infected mice.
Effect of anti-B7-1 and anti-B7-2 MAbs on the levels of IFN-␥ in serum and B. burgdorferi-specific antibodies in infected mice. We then determined the effect of anti-B7-1 and/or anti-B7-2 MAb treatment on the levels of circulating IFN-␥ and the B. burgdorferi-specific antibody levels and their speci- ficity during infection. IFN-␥ levels in the sera of the infected mice were lower in all the experimental groups than in the controls 3, 7, and 14 days after infection (Fig. 3) , in contrast to the RT-PCR data. To determine whether anti-B7-1 or anti-B7-2 treatment affected the antibody response to B. burgdorferi, we measured B. burgdorferi-specific IgM and IgG antibody titers in the sera of the infected animals. We observed no differences in the amount of IgM or IgG produced in the infected mice in response to B. burgdorferi (data not shown). Furthermore, we did not observe any change in the antibody specificity to individual B. burgdorferi antigens: anti-B7-1 and/or B7-2 and control rat IgG-treated mice, as well as untreated B. burgdorferi-infected mice all responded with IgG class antibodies specific for flagellin (41 kDa), P39 (39 kDa), and OspC (22 kDa), typical of this stage of infection (6) .
Effect of anti-B7-1 and/or anti-B7-2 MAb treatment on the development of murine Lyme arthritis and carditis. The effect of treatment with anti-B7-1 and/or anti-B7-2 MAbs on the prevalence and severity of arthritis and carditis was determined by histopathologic evaluation of the heart and joints of B. burgdorferi-infected animals. Carditis was similar in all groups of mice (Table 1) . Arthritis prevalence and severity were determined in 3-and 6-week-old mice because joint inflammation is partially dependent upon age and is more severe in mice infected at 3 weeks of age than in those infected at 6 weeks (4). As expected, the disease was most pronounced when 3-weekold mice were inoculated with B. burgdorferi (Table 1) . Arthritis was equivalent in anti-B7-1 and/or anti-B7-2 MAb-treated (100 g per dose) and control mice of this age (Table 1) . When 6-week-old mice were inoculated, however, a modulation of the disease with antibody treatment was observed (Table 1) . Arthritis in the anti-B7-1 MAb-treated mice was less severe than in the controls in a dose-dependent manner (the mean tibiotarsal arthritis severity scores were 0.7 Ϯ 0.5 [standard deviation] for controls and 0.7 Ϯ 0.9, 0.4 Ϯ 0.2, and 0.2 Ϯ 0.3 for mice treated with 0.1, 0.5, and 1.0 mg/injection, respectively [ Table 1 ]). The severity of arthritis in anti-B7-2 and anti-B7-1-plus-anti-B7-2 MAb-treated groups was increased in comparison with that in controls in a dose-dependent manner (Table 1). In both cases, we observed a similar effect with either MAb treatment: 0.9 Ϯ 0.6 and 0.4 Ϯ 0.4 for 0.1 g/injection in the anti-B7-2 and anti-B7-1-plus-anti-B7-2 groups; 1.4 Ϯ 0.8 and 1.3 Ϯ 0.7 for 0.5 g/injection; and 1.5 Ϯ 0.7 and 1.5 Ϯ 0.6 for 1.0 g/injection ( Table 1) . Analysis of the differences between anti-B7-1 and anti-B7-2 or anti-B7-1-plus-anti-B7-2 MAb-treated infected mice showed a significant difference when groups treated with 0.5 and 1 mg per dose were compared (t test P values: 0.699 for 0.1 mg/dose, 0.03 for 0.5 mg/dose, and 0.005 for 1 mg/dose).
DISCUSSION
The immune response to B. burgdorferi during infection plays an important role in the pathogenesis of Lyme disease (16) (17) (18) , and both innate and acquired immunity and the ability of the spirochete to survive within the host contribute to disease. Reports have correlated the development of Th1 cells against B. burgdorferi with the degree of joint swelling or arthritis (2, 27, 33, 50) , and other studies suggest that antibodies to B. burgdorferi are important in spirochete clearance and resolution of arthritis (5, 6, 42, 44) . In addition, the number of spirochetes within an infected animal contributes to the severity of arthritis (49) . Therefore, a greater understanding of the factors influencing disease, including the development of Tand B-cell responses against B. burgdorferi, will increase our knowledge of the pathogenesis of Lyme arthritis.
Many factors are involved in the differentiation of CD4 ϩ T cells toward Th1 or Th2 phenotypes, including the cytokine environment (IFN-␥ and IL-12 are potent inducers of Th1 responses, while IL-4 produces differentiation toward the Th2 phenotype) (23, 36) , the antigen dose (23, 48) , and costimulation delivered during initial T-cell priming (22, 29, 48) . We have now studied the induction of B7-1 and B7-2 expression (costimulatory molecules required for CD4 ϩ T-cell activation) during infection with B. burgdorferi as well as the effect of the in vivo treatment with B7-1 and/or B7-2 MAb.
In vivo, B. burgdorferi induces upregulation of B7-2 on B cells and B7-1 and B7-2 on macrophages. Upregulation of B7-2 was much greater than that of B7-1, suggesting that B7-2 is more important than B7-1 in the initiation of anti-B. burgdorferi adaptive immune responses or that expression of B7-1 does not need to be upregulated to the same extent as B7-2 to be effective. Experiments performed in vitro with increasing concentrations of B. burgdorferi lysate indicated that the increase in B7 expression was specific (data not shown). The upregulation observed during B. burgdorferi infection, a predominantly extracellular pathogen, contrasts with the effect reported for some intracellular pathogens, in which a costimulatory downregulation is observed (26, 40, 41) .
The effect of the B7-1 and/or B7-2 antibody treatment on infection was dependent upon the age of the mice and the dose VOL. 65, 1997 COSTIMULATION AND THE GENESIS OF LYME BORRELIOSIS 3039
on February 20, 2013 by PENN STATE UNIV http://iai.asm.org/ of antibody used. As expected, 3-week-old mice developed more severe arthritis than did 6-week-old animals. Anti-B7-1 and/or anti-B7-2 did not influence arthritis in the 3-week-old mice. In the 6-week-old animals, anti-B7-1 MAb decreased the severity of arthritis in a dose-dependent fashion without dramatic changes in IFN-␥, IL-4, IL-10, or IL-12 mRNA expression levels. On the other hand, anti-B7-2 or anti-B7-1-plusanti-B7-2 treatments produced an increment in the severity of arthritis that was not accompanied by significant changes in the cytokine mRNA expression pattern of the infected mice splenocytes. Nevertheless, IFN-␥ was decreased in the sera of the anti-B7-1 and/or anti-B7-2 MAb-treated infected mice. This dicotomy suggests that the main sources of this cytokine may not be the cells present in the spleens of B. burgdorferiinfected mice but, rather, other locations in which the spirochetes may reside within the host. The lack of correlation between IFN-␥ production in vivo and disease is somewhat surprising because IFN-␥ levels in serum have been correlated with the severity of murine Lyme arthritis (2, 28, 33) . One possibility is that the cytokine environment in the joints differs from that in the serum or the spleen. The action of the antibodies on cells present in the synovium and its surroundings may be influenced by the different environment and cell types present in that tissue and the expression of proinflammatory cytokines (IL-1, IL-6, IL-8, and tumor necrosis factor alpha) that have been associated with Lyme arthritis (24, 31, 34, 35) , as well as the activation state of neutrophils, macrophages, and endothelial cells (regulation of integrins and adhesion molecules) in the synovial tissue (9, 43) .
The effect of B7-2 may predominate over that of B7-1, because Lyme arthritis is more severe when both anti-B7-1 and anti-B7-2 are administered simultaneously-possibly because of the much higher upregulation of B7-2 on the surface of B cells and macrophages or, alternatively, because B7-2 acts earlier in the activation process.
The differences observed between 3-and 6-week-old mice could be a consequence of the progressive development of the immune system or could occur because the increased severity of arthritis in 3-week-old animals masks the effect of anti-B7-1 and/or B7-2. Moreover, the evolution of murine Lyme arthritis, which peaks in severity between 2 and 4 weeks in both immunocompetent and immunodeficient animals (8) , suggests that the factors influencing disease are likely to be multiple and more dependent upon the innate rather than the acquired immune system in the early stages of disease. Indeed, the acquired immune response may play a more substantial role in the resolution phase of disease (5, 8) .
In conclusion, the data suggest that the T-cell costimulatory signals B7-1 and B7-2 play a role in modulating murine Lyme arthritis. Blocking the B7-1 response resulted in a reduction of arthritis, whereas anti-B7-2 or anti-B7-1-plus-anti-B7-2 treatment increased its severity. These effects were at least partially independent of IFN-␥ production. B7-1 and B7-2 antibodies did not influence Th1 and Th2 differentiation in murine Lyme borreliosis. These differences may be due to the disparity of the systems used and perhaps to the fact that the influence of T-cell differentiation on the genesis of Lyme arthritis is less marked than in other systems (10, 22, 29) . Efforts directed toward a better understanding of the development of the immune response during B. burgdorferi infection should yield more information on the multifactorial pathogenesis of experimental Lyme arthritis. 
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a Infection was assessed by culturing selected tissues. Joints were examined for arthritis and hearts were examined for carditis by microscopy. Results correspond to one representative experiment of two performed.
b See Materials and Methods for an explanation of the scores. c Significant differences in tibiotarsal arthritis severity between anti-B7-1-and anti-B7-2-or anti-B7-1-plus-anti-B7-2 MAb-treated infected mice (t test, P Ͻ 0.05).
